Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of galantamine hydrobromide for cognitive impairment
ChiCTR2400081930Phase 4Recruiting
- Sponsor
- Wenzhou People's Hospital
- Start
- Mar 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of galantamine in confusion, sponsored by Wenzhou People's Hospital. Primary endpoints: Mini Mental State Examination (MMSE) and Activity of Daily Living (ADL) scale. Started Mar 2024; status: recruiting.
02
Drugs
galantamine
03
Conditions
confusion
Beyond the preview
Go deeper on ChiCTR2400081930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081930.